Last week’s initial public offering (IPO) calendar looked full when the week began, but by Friday only three of a dozen deals had priced and begun trading. Four of last week’s potential IPOs have been postponed, three others are expected to price in the coming week, and one other will wait an additional week before trying again.

The companies that did make their debuts last week were Nexvet Biopharma PLC (NASDAQ: NVET), Barington/Hilco Acquisition Corp. (NASDAQ: BHACU), Columbia Pipeline Partners L.P. (NYSE: CPPL) and Easterly Government Properties (NYSE: DEA).

IPO ETF manager Renaissance Capital reported that 17 IPOs have priced in the United States so far this year, down about 37% from a year ago. Total proceeds raised come to $3 billion, down about 52% compared with the same period in 2014. Of the IPOs that have gone off this year, nine have come from the health care sector. Last year’s IPO total came in at $85.2 billion, the highest total in the past 10 years.

Here is a look at the IPOs on the schedule for the coming week.

The first holdover from last week is Infraredx Inc., a cardiovascular imaging company working on the diagnosis and treatment of coronary artery disease. The company plans to offer 4 million shares in an expected price range of $13 to $15 to raise $56 million at a market cap of nearly $200 million. Joint bookrunners for the offering are RBC Capital Markets, Canaccord Genuity and BMO Capital Markets. Co-managers are Oppenheimer and BTIG. Shares are listed as day-to-day and are to begin trading on the Nasdaq under the ticker symbol REDX.

ALSO READ: Credit Suisse’s Top Picks for Huge Upside in 2015

The second holdover is Eyegate Pharmaceuticals Inc., a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating eye diseases. The company has lowered both its number of shares on offer and its price. Eyegate now plans to sell 800,000 shares at an expected price of $6 to raise $5 million at a market cap of $48.3 million. Joint bookrunners for the offering are Aegis Capital and Chardan Capital Markets. No date other than next week has been set for pricing. Shares will trade on the Nasdaq under the ticker symbol EYEG.

Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and is the third of last week’s companies to try again in the coming week. The company plans to offer 4.6 million shares in an expected price range of $13 to $15 to raise $65 million at a market cap of $191.3 million. Joint bookrunners for the offering are Cowen, Piper Jaffray, Canaccord Genuity and Nomura Securities. Shares are listed as day-to-day, to begin trading on the Nasdaq under the ticker symbol ITEK.

The first of the newly scheduled IPOs for the week beginning February 9 is AutoGenomics Inc., a commercial stage molecular diagnostics company. It plans to offer 3.8 million shares in an expected price range of $11 to $13 to raise $45 million at a market cap of around $123 million. Joint bookrunners for the offering are Stifel, Canaccord Genuity and Cantor Fitzgerald. Shares are scheduled to price on Tuesday and begin trading Wednesday on the Nasdaq under the ticker symbol AGMX.

ALSO READ: Insiders Aggressively Buy Shares as Market Rockets Higher

Avenue Financial Holdings Inc. is a bank holding company operating in the Nashville, Tenn., area. The bank plans to offer 2.5 million shares at an IPO price range of $11 to $13 to raise $30 million at a market cap of $120 million. The sole bookrunner for the offering is Keefe Bruyette Woods. Co-managers are Sandler O’Neill and Sterne Agee. Shares are scheduled to price on Tuesday and begin trading Wednesday on the Nasdaq under the ticker symbol AVNU.

Sol-Wind Renewable Power L.P. is a master limited partnership that plans to own, acquire, invest in and manage operating solar and wind power generation assets. The company plans to offer 8.7 million shares in an expected price range of $19 to $21 dollars, raising $174 million, against a market cap of about $200 million. Joint bookrunners for the offering include UBS Investment Bank, Citigroup, Wells Fargo Securities, Credit Suisse, Deutsche Bank and Macquarie Capital. Co-managers are Bonwick Capital, MFR Securities and Williams Capital Group. Shares are scheduled to price on Tuesday and begin trading Wednesday on the New York Stock Exchange under the ticker symbol SLWD.

Arowana Inc. is a blank-check company based in the Cayman Islands that intends to target acquisitions in the Asia-Pacific region, particularly Southeast Asia and Australia. The company is offering 6 million units at $10 per unit. Sole bookrunner for the offering is EarlyBirdCapital. Units are expected to begin trading on the Nasdaq under the ticker symbol ARWA, and rights and warrants will trade under the symbols ARWAR and ARWAW, respectively.

ALSO READ: Merrill Lynch’s 4 Large Cap Banks to Buy With Big Upside Potential

Inovalon Holdings Inc. is a technology company offering a cloud-based analytics and data-driven intervention platform to improve clinical outcomes. The company plans to offer 22.2 million shares at an expected price range of $21 to $24 to raise $500 million at a market cap of $3.25 billion. Joint bookrunners include Goldman Sachs, Morgan Stanley, Citigroup, Bank of America Merrill Lynch and UBS Investment Bank. Co-managers are Piper Jaffray, Wells Fargo Securities and William Blair. Shares are scheduled to price on Wednesday and begin trading Thursday on the NASDAQ under the ticker symbol INOV.

Invitae Corp. plans to aggregate most of the world’s genetic tests into a single service. The company plans to offer 5.4 million shares at an IPO price range of $13 to $15, raising about $75 million at a market cap of $417 million. Sole bookrunner for the offering is J.P. Morgan. Co-managers are Cowen and Leerink Partners. Shares are scheduled to price on Wednesday and begin trading Thursday on the New York Stock Exchange under the ticker symbol NVTA.

Bellerophon Therapeutics LLC is a clinical stage therapeutics company developing treatments for cardiopulmonary and cardiac diseases. The company plans to offer 4 million shares in an expected price range of $14 to $16 to raise $60 million at a market cap of $178.5 million. Joint bookrunners for the offering are Leerink Partners and Cowen. Co-managers are FBR Capital Markets and Suntrust Robinson Humphrey. Shares are scheduled to price on Thursday and begin trading Friday on the Nasdaq under the ticker symbol BLPH.

ALSO READ: Can Coal Make a Comeback?

Great Ajax Corp. is a mortgage real estate investment trust (REIT). It plans to offer 5.8 million shares in an IPO range of $15 to $17 to raise $93.4 million at a market cap of about $260 million. Joint bookrunners are FBR Capital Markets, Sterne Agee and Nomura Securities. Co-managers are Ladenburg Thalmann and MLV. Shares are scheduled to price on Thursday and begin trading Friday on the New York Stock Exchange under the ticker symbol AJX.

The holdover that is waiting another week before trying again is Check-Cap Ltd., an Israel-based clinical stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for colorectal cancer screening.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.